435 related articles for article (PubMed ID: 26110204)
21. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
[TBL] [Abstract][Full Text] [Related]
22. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
[TBL] [Abstract][Full Text] [Related]
23. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients.
Choi WH; Yoo IR; O JH; Kim SH; Chung SK
Br J Radiol; 2011 Jul; 84(1003):593-9. PubMed ID: 21081574
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Value of Axillary Ultrasound, MRI, and
Aktaş A; Gürleyik MG; Aydın Aksu S; Aker F; Güngör S
Eur J Breast Health; 2022 Jan; 18(1):37-47. PubMed ID: 35059590
[TBL] [Abstract][Full Text] [Related]
26. Predictors determining the status of axilla in breast cancer: Where is PET/CT on that?
Ozgur Aytac H; Colacoglu T; Nihal Nursal G; Zafer Nursal T; Aka Bolat F; Yabanoglu H; Yildirim S; Moray G
J BUON; 2015; 20(5):1295-303. PubMed ID: 26537078
[TBL] [Abstract][Full Text] [Related]
27. Discordant results in
Parisse-Di Martino S; Faure C; Mognetti T
Cancer Treat Res Commun; 2021; 27():100344. PubMed ID: 33636590
[TBL] [Abstract][Full Text] [Related]
28. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
[TBL] [Abstract][Full Text] [Related]
29. Positron emission tomography-computed tomography in the detection of axillary lymph node metastasis in patients with early stage breast cancer.
Chae BJ; Bae JS; Kang BJ; Kim SH; Jung SS; Song BJ
Jpn J Clin Oncol; 2009 May; 39(5):284-9. PubMed ID: 19318373
[TBL] [Abstract][Full Text] [Related]
30. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of 18F-FDG PET/CT and ultrasonography in the diagnosis of breast cancer and axillary lymph node metastasis.
He X; Sun L; Huo Y; Shao M; Ma C
Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):429-437. PubMed ID: 25823388
[TBL] [Abstract][Full Text] [Related]
32. Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging.
Grueneisen J; Nagarajah J; Buchbender C; Hoffmann O; Schaarschmidt BM; Poeppel T; Forsting M; Quick HH; Umutlu L; Kinner S
Invest Radiol; 2015 Aug; 50(8):505-13. PubMed ID: 26115367
[TBL] [Abstract][Full Text] [Related]
33. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
[TBL] [Abstract][Full Text] [Related]
34. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.
Straver ME; Aukema TS; Olmos RA; Rutgers EJ; Gilhuijs KG; Schot ME; Vogel WV; Peeters MJ
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1069-76. PubMed ID: 20130860
[TBL] [Abstract][Full Text] [Related]
35. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
[TBL] [Abstract][Full Text] [Related]
36. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases.
Shao M; Zi J; Wen G
J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884
[TBL] [Abstract][Full Text] [Related]
37. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
38. (18)F-FDG PET/CT-positive internal mammary lymph nodes: pathologic correlation by ultrasound-guided fine-needle aspiration and assessment of associated risk factors.
Wang CL; Eissa MJ; Rogers JV; Aravkin AY; Porter BA; Beatty JD
AJR Am J Roentgenol; 2013 May; 200(5):1138-44. PubMed ID: 23617501
[TBL] [Abstract][Full Text] [Related]
39. Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim 18F-FDG PET/CT and MRI.
Pahk K; Kim S; Choe JG
Nucl Med Commun; 2015 Sep; 36(9):887-91. PubMed ID: 25932536
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology.
Heusch P; Nensa F; Schaarschmidt B; Sivanesapillai R; Beiderwellen K; Gomez B; Köhler J; Reis H; Ruhlmann V; Buchbender C
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):42-8. PubMed ID: 25112399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
